PRP38 domain containing A pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PRPF38AP2 profile across patient tissues and cancer cell-line models. PRPF38AP2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PRPF38AP2 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, PRPF38AP2 RNA expression shows 6,458 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, COAD, and STAD as cancer lineages where PRPF38AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPF38AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPF38AP2 survival associations across molecular data types. PRPF38AP2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPF38AP2 RNA expression–survival associations across cancer types. High PRPF38AP2 expression shows unfavorable associations in LUAD, KIRC, OV, CHOL, READ and THCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PRPF38AP2 RNA expression.
This table summarizes PRPF38AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRPF38AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPF38AP2 shows lower tumor expression in KIRC and LUSC and higher tumor expression in COAD and HNSC. The COAD box plot shows higher PRPF38AP2 RNA expression in tumor versus normal tissue (log2 FC = +0.116, t-test p = .028).
This table shows molecular features associated with PRPF38AP2 in patient tissues and cancer cell lines. In patient samples, PRPF38AP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
